SOLVENTUM CORP

Solventum Corp lifts 2026 guidance, posts 2.2% revenue growth, and plans a Health Information Systems spin‑off to sharpen focus on MedTech.

Solventum Corp’s Q4/2025 earnings release on Feb 26, 2026 promises key insights into its $13.5 B market cap, P/E 8.86, and evolving health‑care innovation strategy.

Stifel raises Solventum Corp’s target to $105, citing strong valuation, cash‑flow and growth in the healthcare microfiltration market. Click to see why this upgrade matters.

Solventum Corp, a 2023‑born healthcare firm, balances Medsurg, Dental and Health‑IT solutions with modest P/E and active conference presence, positioning itself as a growth potential in a competitive market.

Solventum Corp partners with Jiuzi Holdings to launch a $1 billion Bitcoin treasury, boosting institutional yields, compliant DeFi access, and RWA innovation in the health‑care sector.

Solventum Corp reported strong Q1 2025 financials, exceeding earnings and revenue estimates despite facing tariff challenges, with shares surging 6.41% on the news.

Solventum Corp navigated tariff challenges to deliver a strong Q1 2025 performance, with its stock surging 6.41% and beating earnings expectations despite a $100 million tariff hit.

Solventum Corp has reported a strong start to 2025, with a 6.41% stock gain and robust organic growth, despite facing tariff challenges, positioning the company for future success.